E Fund Management Co. Ltd. Has $228,000 Stock Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)

E Fund Management Co. Ltd. grew its stake in shares of Verve Therapeutics, Inc. (NASDAQ:VERV) by 13.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 16,378 shares of the company’s stock after acquiring an additional 1,981 shares during the period. E Fund Management Co. Ltd.’s holdings in Verve Therapeutics were worth $228,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. SG Americas Securities LLC acquired a new position in Verve Therapeutics during the third quarter worth $248,000. Mirae Asset Global Investments Co. Ltd. increased its position in Verve Therapeutics by 8.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 212,104 shares of the company’s stock worth $2,812,000 after buying an additional 17,277 shares during the period. Teacher Retirement System of Texas lifted its holdings in shares of Verve Therapeutics by 10.8% during the third quarter. Teacher Retirement System of Texas now owns 12,058 shares of the company’s stock worth $160,000 after buying an additional 1,174 shares during the last quarter. Principal Financial Group Inc. boosted its position in shares of Verve Therapeutics by 18.0% in the third quarter. Principal Financial Group Inc. now owns 16,847 shares of the company’s stock valued at $223,000 after acquiring an additional 2,566 shares during the period. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its stake in shares of Verve Therapeutics by 5.6% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 16,479 shares of the company’s stock worth $219,000 after acquiring an additional 871 shares during the last quarter. 97.11% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

VERV has been the subject of several research analyst reports. Stifel Nicolaus cut their target price on shares of Verve Therapeutics from $56.00 to $40.00 and set a “buy” rating for the company in a research note on Wednesday, April 3rd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $35.00 price objective on shares of Verve Therapeutics in a research report on Wednesday, February 28th. Finally, HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Verve Therapeutics in a research report on Thursday. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $33.00.

Verve Therapeutics Stock Performance

Shares of Verve Therapeutics stock opened at $6.42 on Friday. Verve Therapeutics, Inc. has a twelve month low of $5.84 and a twelve month high of $21.42. The firm has a market cap of $538.77 million, a P/E ratio of -2.04 and a beta of 1.94. The firm’s 50-day simple moving average is $10.10 and its 200-day simple moving average is $11.85.

Verve Therapeutics (NASDAQ:VERV) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.11. The company had revenue of $5.70 million for the quarter, compared to the consensus estimate of $2.11 million. Verve Therapeutics had a negative return on equity of 39.33% and a negative net margin of 1,701.70%. The firm’s revenue was up 305.6% compared to the same quarter last year. On average, equities analysts forecast that Verve Therapeutics, Inc. will post -2.92 earnings per share for the current fiscal year.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.